Evidence map›Paper›PMID 35248919›Full record

ArticleTranslational oncology2022

Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis.

Camila Bragança Xavier, Carlos Diego Holanda Lopes, Guilherme Harada, Eduardo Dante Bariani Peres, Artur Katz, Denis Leonardo Jardim

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Camila Bragança XavierOncology Center - Hospital Sírio-Libanês, São Paulo, Brazil.
Carlos Diego Holanda LopesOncology Center - Hospital Sírio-Libanês, São Paulo, Brazil.
Guilherme HaradaOncology Center - Hospital Sírio-Libanês, São Paulo, Brazil.
Eduardo Dante Bariani PeresCardiology Center - Hospital Sírio-Libanês, São Paulo, Brazil.
Artur KatzOncology Center - Hospital Sírio-Libanês, São Paulo, Brazil.
Denis Leonardo JardimOncology Center - Hospital Sírio-Libanês, São Paulo, Brazil. Electronic address: jardimde@gmail.com.
Hospital Sírio-Libanês · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmune checkpoint inhibitors may be associated with multiple immune-related toxicities. Cardiovascular adverse effects are underreported in clinical trials.

methodsWe conducted a systematic review and meta-analysis to evaluate cardiovascular adverse effects incidence among patients with solid tumors receiving immune checkpoint inhibitors in randomized clinical trials and the relative risk of presenting these effects compared to placebo or best supportive care. The search was conducted through MEDLINE, Embase, and Scopus databases from January 1st, 2010 until July 1st, 2020. Outcomes were reported following Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines.

results57 randomized clinical trials including 12,118 patients were included. All grade CV AEs incidence rate was 8.32% (95% CI = 6.35%-10.53%). When only grade 3-5 CV AEs were considered, ICIs were significantly associated with increased risk than placebo or BSC (RR = 1.36; 95% CI = 1.06-1.73; p = 0.01).

conclusionThis meta-analysis corroborates the hypothesis of increased CV risk related to immune checkpoint inhibitors.

Indexed as

Adverse effects, BSCBest supportive care, CTCAECardiovascular, FAERSCardiovascular toxicityCheckpoint blockadeCommon toxicity criteria, CTLA-4Cytotoxic t-lymphocyte-associated antigen 4, CVImmune checkpoint inhibitorsImmune checkpoint inhibitors, PRISMAMeta-analysis, abbreviations, AESPreferred Reporting Items for Systematic Reviews and Meta-analyses, RCTsprogrammed cell death ligand 1, RRprogrammed cell death protein 1, PD-L1randomized clinical trials, PD-1relative riskU.S. food and drug administration adverse events reporting system, ICIS

Identifiers

PMID35248919
PMCPMC8898968
OpenAlexW4214898225

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.